Business Description
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotech company founded in 2002 that uses RNA interference technology to develop medicines that silence specific genes responsible for serious diseases. The company currently sells six approved treatments targeting conditions such as hereditary amyloidosis, high cholesterol, hemophilia, and rare liver disorders, while maintaining a deep pipeline of experimental drugs across areas including heart disease, neurological conditions, obesity, and cancer. Alnylam works alongside major pharmaceutical partners including Novartis, Roche, Sanofi, and Regeneron to advance its research and bring new therapies to patients around the world.
